Insulin Biosimilars: The Impact on Rapid-Acting Analogue-Based Therapy

Newer insulin analogs: advances in basal insulin replacement

(2013) Bernard Zinman   DIABETES OBESITY & METABOLISM

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase

(2012) L. Morrow et al.   DIABETES CARE

The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences

(2012) P. D. Home   DIABETES OBESITY & METABOLISM

The Emergence of Biosimilar Insulin Preparations—A Cause for Concern?

(2012) David R. Owens et al.   Diabetes Technology & Therapeutics

Low molecular weight heparins copies: are they considered to be generics or biosimilars?

(2012) Paola Minghetti et al.   DRUG DISCOVERY TODAY

The regulatory framework of biosimilars in the European Union

(2011) Paola Minghetti et al.   DRUG DISCOVERY TODAY

Biosimilars and Regulatory Authorities

(2010) Paola Minghetti et al.   NEPHRON CLINICAL PRACTICE